Orlistat was switched in the Netherlands during 2008, paving the way for the introduction of OTC obesity products. In April 2009, GlaxoSmithKline introduced Alli in the Dutch market, being the sole product available OTC obesity at the time of writing.
The OTC Obesity Products in Netherlands report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Product coverage:
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report? - Get a detailed picture of the Consumer Health industry; - Pinpoint growth sectors and identify factors driving change; - Understand the competitive environment, the market’s major players and leading brands; - Use five-year forecasts to assess how the market is predicted to develop.
